US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
SG10201702445TA
(en)
|
2012-04-25 |
2017-04-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
RS64622B1
(en)
|
2012-05-25 |
2023-10-31 |
Univ California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
CA2877290A1
(en)
|
2012-06-19 |
2013-12-27 |
Daniel F. Voytas |
Gene targeting in plants using dna viruses
|
ES2757623T3
(en)
*
|
2012-07-25 |
2020-04-29 |
Broad Inst Inc |
Inducible DNA binding proteins and genomic disruption tools and applications thereof
|
JP6517143B2
(en)
|
2012-10-23 |
2019-05-22 |
ツールゲン インコーポレイテッド |
Composition for cleaving target DNA comprising guide RNA specific for target DNA and CAS protein encoding nucleic acid or CAS protein, and use thereof
|
KR102006880B1
(en)
|
2012-12-06 |
2019-08-02 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-based genome modification and regulation
|
US8697359B1
(en)
*
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
EP4286402A3
(en)
*
|
2012-12-12 |
2024-02-14 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
PT2896697E
(en)
|
2012-12-12 |
2015-12-31 |
Massachusetts Inst Technology |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
PT2898075E
(en)
|
2012-12-12 |
2016-06-16 |
Harvard College |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
WO2014093718A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
IL239317B
(en)
*
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
SG11201504621RA
(en)
|
2012-12-17 |
2015-07-30 |
Harvard College |
Rna-guided human genome engineering
|
US10138509B2
(en)
|
2013-03-12 |
2018-11-27 |
President And Fellows Of Harvard College |
Method for generating a three-dimensional nucleic acid containing matrix
|
ES2901396T3
(en)
|
2013-03-14 |
2022-03-22 |
Caribou Biosciences Inc |
Nucleic Acid Targeting Nucleic Acid Compositions and Methods
|
US20140273235A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Regents Of The University Of Minnesota |
ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
|
JP2016522679A
(en)
*
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Therapeutic use of genome editing with the CRISPR / Cas system
|
RS58255B1
(en)
|
2013-04-16 |
2019-03-29 |
Regeneron Pharma |
Targeted modification of rat genome
|
WO2014172470A2
(en)
*
|
2013-04-16 |
2014-10-23 |
Whitehead Institute For Biomedical Research |
Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
DK3004349T3
(en)
*
|
2013-05-29 |
2018-06-06 |
Cellectis Sa |
A method for producing precise DNA cleavage using CAS9 nickase activity
|
WO2014197568A2
(en)
*
|
2013-06-04 |
2014-12-11 |
President And Fellows Of Harvard College |
Rna-guideded transcriptional regulation
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
AU2014279694B2
(en)
|
2013-06-14 |
2020-07-23 |
Cellectis |
Methods for non-transgenic genome editing in plants
|
RU2716420C2
(en)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver
|
AU2014281027A1
(en)
|
2013-06-17 |
2016-01-28 |
Massachusetts Institute Of Technology |
Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
|
KR20160044457A
(en)
|
2013-06-17 |
2016-04-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
SG10201710487VA
(en)
|
2013-06-17 |
2018-01-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
KR20230122182A
(en)
*
|
2013-07-09 |
2023-08-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Multiplex rna-guided genome engineering
|
JP2016528890A
(en)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Therapeutic use of genome editing using the CRISPR / Cas system
|
US11306328B2
(en)
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
AU2014306423B2
(en)
|
2013-08-16 |
2019-04-18 |
Massachusetts Institute Of Technology |
Selective delivery of material to cells
|
CN105916989A
(en)
|
2013-08-22 |
2016-08-31 |
纳幕尔杜邦公司 |
A soybean U6 polymerase III promoter and methods of use
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
EP3418379B1
(en)
|
2013-09-18 |
2020-12-09 |
Kymab Limited |
Methods, cells & organisms
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
KR102523466B1
(en)
|
2013-11-07 |
2023-04-20 |
에디타스 메디신, 인코포레이티드 |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
EP4349980A2
(en)
|
2013-12-11 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
WO2015088643A1
(en)
|
2013-12-11 |
2015-06-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
SG10201804976YA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
|
JP6793547B2
(en)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Optimization Function Systems, methods and compositions for sequence manipulation with the CRISPR-Cas system
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
AU2014362248A1
(en)
|
2013-12-12 |
2016-06-16 |
Massachusetts Institute Of Technology |
Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
|
AU2014361834B2
(en)
|
2013-12-12 |
2020-10-22 |
Massachusetts Institute Of Technology |
CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
KR102496984B1
(en)
|
2014-02-11 |
2023-02-06 |
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 |
Crispr enabled multiplexed genome engineering
|
WO2015126927A2
(en)
|
2014-02-18 |
2015-08-27 |
Duke University |
Compositions for the inactivation of virus replication and methods of making and using the same
|
WO2015131101A1
(en)
|
2014-02-27 |
2015-09-03 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
EP3122880B1
(en)
|
2014-03-26 |
2021-05-05 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
CN106460003A
(en)
|
2014-04-08 |
2017-02-22 |
北卡罗来纳州立大学 |
Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
|
CA2949697A1
(en)
*
|
2014-05-20 |
2015-11-26 |
Regents Of The University Of Minnesota |
Method for editing a genetic sequence
|
KR101886381B1
(en)
*
|
2014-05-28 |
2018-08-10 |
기초과학연구원 |
A method for isolating target DNA using inactivated site-specific nuclease
|
WO2015188056A1
(en)
*
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
RU2704283C9
(en)
|
2014-06-06 |
2020-02-07 |
Регенерон Фармасьютикалз, Инк. |
Methods and compositions for modifying target locus
|
WO2015191693A2
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
CA2952121A1
(en)
|
2014-06-13 |
2015-12-17 |
Childrens' Medical Center Corporation |
Products and methods to isolate mitochondria
|
BR112016030145A8
(en)
|
2014-06-23 |
2018-12-11 |
Regeneron Pharma |
methods for assembling at least two nucleic acids and two or more nucleic acids
|
WO2015200555A2
(en)
*
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
US20150376587A1
(en)
*
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
ES2694629T3
(en)
|
2014-06-26 |
2018-12-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for objective genetic modifications and methods of use
|
WO2016007347A1
(en)
|
2014-07-11 |
2016-01-14 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
WO2016011080A2
(en)
*
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
Crispr/cas transcriptional modulation
|
US10457969B2
(en)
*
|
2014-07-21 |
2019-10-29 |
Illumina, Inc. |
Polynucleotide enrichment using CRISPR-Cas systems
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
KR101817482B1
(en)
*
|
2014-08-06 |
2018-02-22 |
주식회사 툴젠 |
Genome editing using campylobacter jejuni crispr/cas system-derived rgen
|
KR101826904B1
(en)
*
|
2014-08-06 |
2018-02-08 |
기초과학연구원 |
Immune-compatible cells created by nuclease-mediated editing of genes encoding Human Leukocyte Antigens
|
US11071289B2
(en)
|
2014-08-14 |
2021-07-27 |
Biocytogen Boston Corp |
DNA knock-in system
|
WO2016033246A1
(en)
*
|
2014-08-27 |
2016-03-03 |
Caribou Biosciences, Inc. |
Methods for increasing cas9-mediated engineering efficiency
|
EP3186375A4
(en)
|
2014-08-28 |
2019-03-13 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
CN104212836A
(en)
*
|
2014-09-18 |
2014-12-17 |
东华大学 |
Method for knocking out mir-505 from mammal cell line
|
CA2964487C
(en)
|
2014-10-15 |
2024-03-19 |
Sage Science, Inc. |
Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation
|
ES2741387T3
(en)
|
2014-10-15 |
2020-02-10 |
Regeneron Pharma |
Methods and compositions for generating or maintaining pluripotent cells
|
JP2017533702A
(en)
|
2014-10-31 |
2017-11-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Delivery of biomolecules to immune cells
|
CA2966731C
(en)
*
|
2014-11-06 |
2023-01-31 |
E. I. Du Pont De Nemours And Company |
Peptide-mediated delivery of rna-guided endonuclease into cells
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
US11352666B2
(en)
|
2014-11-14 |
2022-06-07 |
Institute For Basic Science |
Method for detecting off-target sites of programmable nucleases in a genome
|
WO2016076672A1
(en)
*
|
2014-11-14 |
2016-05-19 |
기초과학연구원 |
Method for detecting off-target site of genetic scissors in genome
|
PT3221457T
(en)
|
2014-11-21 |
2019-06-27 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification using paired guide rnas
|
WO2016089433A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
US9888673B2
(en)
|
2014-12-10 |
2018-02-13 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
JP6814142B2
(en)
*
|
2014-12-16 |
2021-01-13 |
ダニスコ・ユーエス・インク |
Fungal Genome Modification System and Usage
|
AU2015364282B2
(en)
*
|
2014-12-18 |
2021-04-15 |
Integrated Dna Technologies, Inc. |
CRISPR-based compositions and methods of use
|
US10196613B2
(en)
|
2014-12-19 |
2019-02-05 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
KR102530821B1
(en)
|
2014-12-19 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
CA2971626A1
(en)
*
|
2015-01-12 |
2016-07-21 |
Massachusetts Institute Of Technology |
Gene editing through microfluidic delivery
|
CN105985943B
(en)
*
|
2015-03-16 |
2021-07-06 |
中国科学院遗传与发育生物学研究所 |
Method for site-specific modification of plant genome by using non-genetic material
|
WO2016150855A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Danmarks Tekniske Universitet |
Crispr/cas9 based engineering of actinomycetal genomes
|
EP3274453B1
(en)
*
|
2015-03-26 |
2021-01-27 |
Editas Medicine, Inc. |
Crispr/cas-mediated gene conversion
|
CN107567499A
(en)
|
2015-03-27 |
2018-01-09 |
纳幕尔杜邦公司 |
Soybean U6 small nuclear RNAs gene promoter and its purposes in the constitutive expression of plant MicroRNA gene
|
CN107787367B
(en)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
Chemically modified guide RNAs for CRISPR/CAS mediated gene regulation
|
EP3286571B1
(en)
|
2015-04-24 |
2021-08-18 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
KR101785847B1
(en)
|
2015-05-12 |
2017-10-17 |
연세대학교 산학협력단 |
Targeted genome editing based on CRISPR/Cas9 system using short linearized double-stranded DNA
|
EP3095870A1
(en)
|
2015-05-19 |
2016-11-23 |
Kws Saat Se |
Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
|
JP2018516563A
(en)
|
2015-05-29 |
2018-06-28 |
ノース カロライナ ステート ユニバーシティNorth Carolina State University |
Method for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acid
|
EP3303585A4
(en)
|
2015-06-03 |
2018-10-31 |
Board of Regents of the University of Nebraska |
Dna editing using single-stranded dna
|
CN116334142A
(en)
|
2015-06-09 |
2023-06-27 |
爱迪塔斯医药公司 |
CRISPR/CAS related methods and compositions for improving transplantation
|
CA2983874C
(en)
|
2015-06-15 |
2022-06-21 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
KR102575342B1
(en)
|
2015-06-18 |
2023-09-05 |
더 브로드 인스티튜트, 인코퍼레이티드 |
CRISPR enzyme mutations that reduce off-target effects
|
US11414657B2
(en)
|
2015-06-29 |
2022-08-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
CN107922911A
(en)
|
2015-07-09 |
2018-04-17 |
麻省理工学院 |
Material is delivered to cytode
|
JP6937740B2
(en)
*
|
2015-07-28 |
2021-09-22 |
ダニスコ・ユーエス・インク |
Genome editing system and usage
|
IL295616A
(en)
|
2015-07-31 |
2022-10-01 |
Us Health |
Modified cells and methods of therapy
|
US9580727B1
(en)
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
EP3334746B1
(en)
|
2015-08-14 |
2021-11-24 |
The University Of Sydney |
Connexin 45 inhibition for therapy
|
IL288662B2
(en)
*
|
2015-08-25 |
2023-09-01 |
Univ Duke |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
WO2017053312A1
(en)
*
|
2015-09-21 |
2017-03-30 |
The Regents Of The University Of California |
Compositions and methods for target nucleic acid modification
|
CA2999500A1
(en)
|
2015-09-24 |
2017-03-30 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
EP3356533A1
(en)
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
KR101829885B1
(en)
*
|
2015-10-06 |
2018-03-30 |
기초과학연구원 |
A method for preparing a genome-edited plant from protoplasts
|
CA2996329A1
(en)
*
|
2015-10-20 |
2017-04-27 |
Pioneer Hi-Bred International, Inc. |
Restoring function to a non-functional gene product via guided cas systems and methods of use
|
DK3350327T3
(en)
|
2015-10-23 |
2019-01-21 |
Caribou Biosciences Inc |
CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID
|
IL258821B
(en)
|
2015-10-23 |
2022-07-01 |
Harvard College |
Nucleobase editors and uses thereof
|
CA3004285A1
(en)
|
2015-11-03 |
2017-05-11 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
KR101885901B1
(en)
*
|
2015-11-13 |
2018-08-07 |
기초과학연구원 |
RGEN RNP delivery method using 5'-phosphate removed RNA
|
CN108699101B
(en)
*
|
2015-11-20 |
2022-04-19 |
塞奇科学股份有限公司 |
Preparative electrophoresis method for targeted purification of genomic DNA fragments
|
CN106811479B
(en)
*
|
2015-11-30 |
2019-10-25 |
中国农业科学院作物科学研究所 |
The system and its application of Herbicide Resistant Rice are obtained using CRISPR/Cas9 system pointed decoration als gene
|
WO2017095946A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes
|
MX2018005392A
(en)
*
|
2015-12-04 |
2019-05-30 |
Caribou Biosciences Inc |
Engineered nucleic-acid targeting nucleic acids.
|
CN106845151B
(en)
*
|
2015-12-07 |
2019-03-26 |
中国农业大学 |
The screening technique and device of CRISPR-Cas9 system sgRNA action target spot
|
WO2017099494A1
(en)
*
|
2015-12-08 |
2017-06-15 |
기초과학연구원 |
Genome editing composition comprising cpf1, and use thereof
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
EA201891619A1
(en)
|
2016-01-11 |
2019-02-28 |
Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити |
CHEMERAL PROTEINS AND METHODS OF REGULATING GENE EXPRESSION
|
EA201891614A1
(en)
|
2016-01-11 |
2019-02-28 |
Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити |
CHEMICAL PROTEINS AND METHODS OF IMMUNOTHERAPY
|
CN109414001A
(en)
*
|
2016-01-15 |
2019-03-01 |
杰克逊实验室 |
Pass through the non-human mammal for the genetic modification that the multi-cycle electroporation of CAS9 albumen generates
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
CN117731805A
(en)
*
|
2016-03-30 |
2024-03-22 |
因特利亚治疗公司 |
Lipid nanoparticle formulations for CRISPR/CAS components
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
WO2017189525A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
CN107326046A
(en)
*
|
2016-04-28 |
2017-11-07 |
上海邦耀生物科技有限公司 |
A kind of method for improving foreign gene homologous recombination efficiency
|
NZ747857A
(en)
|
2016-05-20 |
2023-01-27 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide rnas
|
CA3025523A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
KR20220147710A
(en)
|
2016-06-02 |
2022-11-03 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Using programmable dna binding proteins to enhance targeted genome modification
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
US20190177710A1
(en)
*
|
2016-06-15 |
2019-06-13 |
Toolgen Incorporated |
Method For Screening Target Specific Nuclease Using Multi-Target System Of On-Target And Off-Target And Use Thereof
|
CA3028158A1
(en)
|
2016-06-17 |
2017-12-21 |
The Broad Institute, Inc. |
Type vi crispr orthologs and systems
|
US20190330603A1
(en)
*
|
2016-06-17 |
2019-10-31 |
Genesis Technologies Limited |
Crispr-cas system, materials and methods
|
AU2017282623B2
(en)
*
|
2016-06-20 |
2023-09-21 |
Keygene N.V. |
Method for targeted DNA alteration in plant cells
|
CA3029254A1
(en)
|
2016-06-24 |
2017-12-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for generating barcoded combinatorial libraries
|
BR112019000107A2
(en)
*
|
2016-07-05 |
2019-04-09 |
The Johns Hopkins University |
crispr / cas9 based compositions and methods for cancer treatment
|
EP3484994A4
(en)
*
|
2016-07-13 |
2020-01-22 |
DSM IP Assets B.V. |
A crispr-cas system for an algal host cell
|
US20190309283A1
(en)
*
|
2016-07-19 |
2019-10-10 |
Biodynamics Laboratory, Inc. |
Method for preparing long-chain single-stranded dna
|
EP3492096A4
(en)
|
2016-07-28 |
2020-04-15 |
Institute for Basic Science |
Pharmaceutical composition for treating ocular diseases, containing cas9 protein and guide rna
|
AU2017302657A1
(en)
|
2016-07-29 |
2019-02-14 |
Regeneron Pharmaceuticals, Inc. |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
AU2017305404B2
(en)
|
2016-08-02 |
2023-11-30 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290 associated disease
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
IL264565B1
(en)
|
2016-08-03 |
2024-03-01 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
KR101710026B1
(en)
|
2016-08-10 |
2017-02-27 |
주식회사 무진메디 |
Composition comprising delivery carrier of nano-liposome having Cas9 protein and guide RNA
|
KR101856345B1
(en)
*
|
2016-08-24 |
2018-06-20 |
경상대학교산학협력단 |
Method for generation of APOBEC3H and APOBEC3CH double-knocked out cat using CRISPR/Cas9 system
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
WO2018068053A2
(en)
|
2016-10-07 |
2018-04-12 |
Integrated Dna Technologies, Inc. |
S. pyogenes cas9 mutant genes and polypeptides encoded by same
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
KR101997116B1
(en)
|
2016-10-14 |
2019-07-05 |
연세대학교 산학협력단 |
Guide RNA complementary to KRAS gene and use thereof
|
JP2019530464A
(en)
|
2016-10-14 |
2019-10-24 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Nucleobase editor AAV delivery
|
GB2605883B
(en)
|
2016-10-18 |
2023-03-15 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
WO2018144097A1
(en)
|
2016-11-04 |
2018-08-09 |
Akeagen Llc |
Genetically modified non-human animals and methods for producing heavy chain-only antibodies
|
CA3042259A1
(en)
|
2016-11-04 |
2018-05-11 |
Flagship Pioneering Innovations V. Inc. |
Novel plant cells, plants, and seeds
|
BR112019009725A2
(en)
*
|
2016-11-14 |
2019-11-19 |
Toolgen Incorporated |
artificially manipulated sc function control system
|
AU2017364084A1
(en)
|
2016-11-22 |
2019-05-16 |
Integrated Dna Technologies, Inc. |
CRISPR/Cpf1 systems and methods
|
US11293022B2
(en)
|
2016-12-12 |
2022-04-05 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
KR101748575B1
(en)
*
|
2016-12-16 |
2017-06-20 |
주식회사 엠젠플러스 |
INSulin gene knockout diabetes mellitus or diabetic complications animal model and a method for producing the same
|
CN110325643A
(en)
*
|
2016-12-22 |
2019-10-11 |
株式会社图尔金 |
The plant and its production method rich in oleic acid with the FAD2 through gene modification
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
KR102151065B1
(en)
*
|
2016-12-23 |
2020-09-02 |
기초과학연구원 |
Composition and method for base editing in animal embryos
|
JP6994730B2
(en)
*
|
2016-12-26 |
2022-02-04 |
独立行政法人酒類総合研究所 |
Genome editing method for filamentous fungus genome editing by direct introduction of protein
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
KR102515727B1
(en)
*
|
2017-01-11 |
2023-03-30 |
주식회사 툴젠 |
Composition and method for inserting specific nucleic acid sequence into target nucleic acid using overlapping guide nucleic acid
|
EP3571321A1
(en)
|
2017-01-23 |
2019-11-27 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
US11624071B2
(en)
|
2017-01-28 |
2023-04-11 |
Inari Agriculture Technology, Inc. |
Method of creating a plurality of targeted insertions in a plant cell
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
WO2018164457A1
(en)
*
|
2017-03-06 |
2018-09-13 |
기초과학연구원 |
Composition containing c2cl endonuclease for dielectric calibration and method for dielectric calibration using same
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
CN110914310A
(en)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
Cytosine to guanine base editor
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
CN110506203A
(en)
|
2017-04-07 |
2019-11-26 |
塞奇科学股份有限公司 |
For purifying the system and method to detect genetic structure variation by using integrated electrophoresis DNA
|
CA3059643A1
(en)
*
|
2017-04-13 |
2018-10-18 |
Cellectis |
New sequence specific reagents targeting ccr5 in primary hematopoietic cells
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
EP3615672A1
(en)
|
2017-04-28 |
2020-03-04 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
EP3635102A1
(en)
|
2017-06-05 |
2020-04-15 |
Regeneron Pharmaceuticals, Inc. |
B4galt1 variants and uses thereof
|
CN108977442B
(en)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
System for DNA editing and application thereof
|
US10428319B2
(en)
|
2017-06-09 |
2019-10-01 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
CA3066750A1
(en)
|
2017-06-13 |
2018-12-20 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP2020530307A
(en)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
Adeno-associated virus vector for gene therapy
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
CN107488710B
(en)
*
|
2017-07-14 |
2020-09-22 |
上海吐露港生物科技有限公司 |
Application of Cas protein, and detection method and kit of target nucleic acid molecule
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
CA3068072A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
CA3067872A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof
|
CN110891419A
(en)
|
2017-07-31 |
2020-03-17 |
瑞泽恩制药公司 |
Evaluation of CRISPR/CAS-induced in vivo recombination with exogenous donor nucleic acids
|
JP7207665B2
(en)
|
2017-08-04 |
2023-01-18 |
北京大学 |
TALE RVDs that specifically recognize DNA bases modified by methylation and uses thereof
|
WO2019028686A1
(en)
|
2017-08-08 |
2019-02-14 |
北京大学 |
Gene knockout method
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
US11713452B2
(en)
|
2017-09-08 |
2023-08-01 |
University Of North Texas Health Science Center |
Engineered CAS9 variants
|
CN109517796A
(en)
|
2017-09-18 |
2019-03-26 |
博雅辑因(北京)生物科技有限公司 |
A kind of gene editing T cell and application thereof
|
US11572574B2
(en)
|
2017-09-28 |
2023-02-07 |
Toolgen Incorporated |
Artificial genome manipulation for gene expression regulation
|
EP3690047A4
(en)
*
|
2017-09-28 |
2021-11-03 |
Toolgen Incorporated |
Artificial genome manipulation for gene expression regulation
|
CA3077255A1
(en)
*
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
KR102207352B1
(en)
*
|
2017-09-29 |
2021-01-26 |
서울대학교산학협력단 |
klotho knock-out porcine Models for klotho deficiency disease and the Use thereof
|
MX2020003589A
(en)
|
2017-09-29 |
2020-07-22 |
Regeneron Pharma |
Non-human animals comprising a humanized.
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
SG11202003798TA
(en)
|
2017-10-27 |
2020-05-28 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
CN109722415B
(en)
|
2017-10-27 |
2021-01-26 |
博雅辑因(北京)生物科技有限公司 |
Hematopoietic stem cell culture composition, culture medium and hematopoietic stem cell culture method
|
CN108192956B
(en)
*
|
2017-11-17 |
2021-06-01 |
东南大学 |
Cas9 nuclease-based DNA detection and analysis method and application thereof
|
CN111836894B
(en)
|
2017-11-21 |
2023-11-10 |
基恩科雷有限责任公司 |
Compositions for genome editing using CRISPR/Cpf1 systems and uses thereof
|
WO2019138083A1
(en)
|
2018-01-12 |
2019-07-18 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
JP7075170B2
(en)
*
|
2018-01-23 |
2022-05-25 |
インスティチュート フォー ベーシック サイエンス |
Extended single guide RNA and its uses
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
KR102086689B1
(en)
*
|
2018-02-06 |
2020-03-09 |
주식회사 진씨커 |
Kit for isolation of mutant cell free DNA and method for isolation of mutant cell free DNA using the same
|
WO2019156475A1
(en)
*
|
2018-02-06 |
2019-08-15 |
주식회사 진씨커 |
Mutant cell-free dna isolation kit and mutant cell-free dna isolation method using same
|
KR20240038811A
(en)
|
2018-03-19 |
2024-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
Transcription modulation in animals using crispr/cas systems
|
AU2019255789A1
(en)
|
2018-04-19 |
2020-10-22 |
The Regents Of The University Of California |
Compositions and methods for gene editing
|
WO2019206233A1
(en)
*
|
2018-04-25 |
2019-10-31 |
中国农业大学 |
Rna-edited crispr/cas effector protein and system
|
GB2589246A
(en)
|
2018-05-16 |
2021-05-26 |
Synthego Corp |
Methods and systems for guide RNA design and use
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
KR102035654B1
(en)
*
|
2018-07-23 |
2019-10-24 |
대한민국 |
Novel mutant insect cell line producing antimicrobial peptide or a preparation method thereof
|
US11479762B1
(en)
|
2018-08-31 |
2022-10-25 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
CA3111477A1
(en)
*
|
2018-09-12 |
2020-03-19 |
Institute For Basic Science |
Composition for inducing death of cells having mutated gene, and method for inducing death of cells having mutated gene by using composition
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
KR102081962B1
(en)
*
|
2018-10-11 |
2020-02-26 |
충남대학교 산학협력단 |
Composition for cleaving amyloid precursor protein gene
|
MX2021004278A
(en)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Compositions and methods for transgene expression from an albumin locus.
|
JP2022512726A
(en)
|
2018-10-18 |
2022-02-07 |
インテリア セラピューティクス,インコーポレーテッド |
Nucleic acid constructs and usage
|
AU2019360270A1
(en)
|
2018-10-18 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX.
|
JP2022505381A
(en)
|
2018-10-18 |
2022-01-14 |
インテリア セラピューティクス,インコーポレーテッド |
Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency
|
KR20210129033A
(en)
*
|
2018-10-29 |
2021-10-27 |
차이나 어그리컬처럴 유니버시티 |
Novel CRISPR/Cas12f Enzymes and Systems
|
WO2020089448A1
(en)
*
|
2018-11-01 |
2020-05-07 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
EP3650557B1
(en)
*
|
2018-11-07 |
2021-10-20 |
Justus-Liebig-Universität Gießen |
Method for determination of restriction efficiency of endonucleases mediating double-strand breaks in dna target sequences
|
EP3882347A4
(en)
*
|
2018-11-16 |
2022-03-02 |
Osaka University |
Method for producing genome-edited cells
|
KR20200071198A
(en)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Development of new adoptive T cell immunotherapy by modification of Nrf2 expression
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
EP3896155A4
(en)
*
|
2018-12-12 |
2022-08-17 |
Kyushu University, National University Corporation |
Production method for genome-edited cells
|
AU2019398351A1
(en)
|
2018-12-14 |
2021-06-03 |
Pioneer Hi-Bred International, Inc. |
Novel CRISPR-Cas systems for genome editing
|
JP7449291B2
(en)
|
2018-12-20 |
2024-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Nuclease-mediated repeat expansion
|
JP2022516647A
(en)
*
|
2019-01-07 |
2022-03-01 |
クリスプ-エイチアール セラピューティクス, インコーポレイテッド |
Non-toxic CAS9 enzyme and its uses
|
CN109868275A
(en)
*
|
2019-03-12 |
2019-06-11 |
中国农业大学 |
The method of sheep FGF5 gene knockout and site-directed integration MTNR1A gene that CRISPR/Cas9 is mediated
|
EP4317950A3
(en)
|
2019-03-18 |
2024-04-17 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
IL286359B1
(en)
|
2019-03-18 |
2024-02-01 |
Regeneron Pharma |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
WO2020191239A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
BR112021019512A2
(en)
|
2019-04-03 |
2022-02-15 |
Regeneron Pharma |
Methods for inserting an antigen-binding protein coding sequence and for treating or prophylaxis of a disease in an animal, animal, cell, genome, exogenous donor nucleic acid, safe harbor gene, and nuclease agent or a or more nucleic acids
|
WO2020206134A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
US11737435B2
(en)
|
2019-04-04 |
2023-08-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
EP3964579A4
(en)
|
2019-04-30 |
2023-07-26 |
EdiGene (GuangZhou) Inc. |
Method for predicting effectiveness of treatment of hemoglobinopathy
|
US11692197B2
(en)
|
2019-05-06 |
2023-07-04 |
Inari Agriculture Technology, Inc. |
Delivery of biological molecules to plant cells
|
CN111304180B
(en)
*
|
2019-06-04 |
2023-05-26 |
山东舜丰生物科技有限公司 |
Novel DNA nucleic acid cutting enzyme and application thereof
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
MX2021015122A
(en)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus.
|
CA3137765A1
(en)
|
2019-06-14 |
2020-12-17 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
EP3990633A1
(en)
|
2019-06-25 |
2022-05-04 |
Inari Agriculture Technology, Inc. |
Improved homology dependent repair genome editing
|
CN115244176A
(en)
*
|
2019-08-19 |
2022-10-25 |
钟明宏 |
Conjugates of guide RNA-CAS protein complexes
|
WO2021043278A1
(en)
|
2019-09-04 |
2021-03-11 |
博雅辑因(北京)生物科技有限公司 |
Method for evaluating gene editing therapy based on off-target assessment
|
US20210079394A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
EP4041894A1
(en)
|
2019-09-23 |
2022-08-17 |
Omega Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
|
CN114391040A
(en)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
CA3153197A1
(en)
|
2019-10-03 |
2021-04-08 |
Ryan T. Gill |
Crispr systems with engineered dual guide nucleic acids
|
WO2021092130A1
(en)
*
|
2019-11-05 |
2021-05-14 |
Pairwise Plants Services, Inc. |
Compositions and methods for rna-encoded dna-replacement of alleles
|
EP4054651A1
(en)
|
2019-11-08 |
2022-09-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr and aav strategies for x-linked juvenile retinoschisis therapy
|
JP7448120B2
(en)
*
|
2019-11-14 |
2024-03-12 |
国立研究開発法人農業・食品産業技術総合研究機構 |
Method for introducing genome editing enzymes into plant cells using plasma
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
WO2021108442A2
(en)
*
|
2019-11-27 |
2021-06-03 |
The Regents Of The University Of California |
Modulators of cas9 polypeptide activity and methods of use thereof
|
US20230054266A1
(en)
|
2019-12-30 |
2023-02-23 |
Edigene Biotechnology Inc. |
Method for purifying ucart cell and use thereof
|
EP4086340A1
(en)
|
2019-12-30 |
2022-11-09 |
Edigene Biotechnology Inc. |
Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
|
CA3167681A1
(en)
*
|
2020-01-14 |
2021-07-22 |
Toolgen Incorporated |
Cells having high adaptability under hypoxic conditions, and use thereof
|
US20230053781A1
(en)
|
2020-01-14 |
2023-02-23 |
Toolgen Incorporated |
Pharmaceutical composition for preventing or treating alzheimer's and use thereof
|
WO2021163515A1
(en)
*
|
2020-02-12 |
2021-08-19 |
Temple University - Of The Commonwealth System Of Higher Education |
Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells
|
KR20210109384A
(en)
|
2020-02-27 |
2021-09-06 |
주식회사 엘지화학 |
Method for increasing gene editing efficiency in plant using protoplasts
|
CN115485385A
(en)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
Methods and compositions for sensitizing tumor cells to immunotherapy
|
JP2023517326A
(en)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス, インコーポレイテッド |
Compositions and methods for modulating forkhead box P3 (FOXP3) gene expression
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
WO2021202938A1
(en)
|
2020-04-03 |
2021-10-07 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
DE112021002672T5
(en)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
|
CN111690720B
(en)
*
|
2020-06-16 |
2021-06-15 |
山东舜丰生物科技有限公司 |
Method for detecting target nucleic acid using modified single-stranded nucleic acid
|
EP4256052A1
(en)
|
2020-12-02 |
2023-10-11 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
KR20220081949A
(en)
*
|
2020-12-09 |
2022-06-16 |
재단법인 아산사회복지재단 |
Guide RNA of which on-target activity is maintained and off-target activity decrease and use thereof
|
IL303892A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Innovations V Inc |
In vitro assembly of anellovirus capsids enclosing rna
|
TW202235615A
(en)
|
2020-12-30 |
2022-09-16 |
美商英特利亞醫療公司 |
Engineered t cells
|
KR102285906B1
(en)
*
|
2021-02-18 |
2021-08-04 |
주식회사 엔에이피 |
Composition for inducing large mouth bass sterility for management of disturbing fish species in aquatic ecosystem
|
EP4337769A1
(en)
|
2021-05-10 |
2024-03-20 |
SQZ Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
KR102616916B1
(en)
*
|
2021-05-11 |
2023-12-21 |
주식회사 애이마 |
Guide RNA for detecting oncogenic mutations and uses thereof
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
US20230052243A1
(en)
|
2021-06-02 |
2023-02-16 |
Lyell Immunopharma, Inc. |
Nr4a-deficient cells expressing c-jun and uses thereof
|
KR102618072B1
(en)
|
2021-06-15 |
2023-12-28 |
대한민국 |
Guide RNA for editing vernalization gene and use thereof
|
CA3223311A1
(en)
|
2021-06-18 |
2022-12-22 |
Andrea BARGHETTI |
Compositions and methods for targeting, editing or modifying human genes
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
AU2022306557A1
(en)
|
2021-07-09 |
2024-01-25 |
Toolgen Incorporated |
Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof
|
WO2023008933A1
(en)
|
2021-07-29 |
2023-02-02 |
주식회사 툴젠 |
Hemocompatible mesenchymal stem cells, preparation method therefor and use thereof
|
CN113584134B
(en)
*
|
2021-09-06 |
2024-01-30 |
青岛金斯达生物技术有限公司 |
Isothermal nucleic acid detection system based on CRISPR-Cas9, and method and application thereof
|
CA3230927A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023064924A1
(en)
|
2021-10-14 |
2023-04-20 |
Codiak Biosciences, Inc. |
Modified producer cells for extracellular vesicle production
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023122800A1
(en)
|
2021-12-23 |
2023-06-29 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150620A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Crispr-mediated transgene insertion in neonatal cells
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
CN114410609B
(en)
*
|
2022-03-29 |
2022-07-12 |
舜丰生物科技(海南)有限公司 |
Cas protein with improved activity and application thereof
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023205844A1
(en)
*
|
2022-04-26 |
2023-11-02 |
Peter Maccallum Cancer Institute |
Nucleic acids and uses thereof
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023225410A2
(en)
|
2022-05-20 |
2023-11-23 |
Artisan Development Labs, Inc. |
Systems and methods for assessing risk of genome editing events
|
WO2023230570A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating genetic drivers
|
WO2023230573A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of immune responses
|
WO2023230549A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of tumor suppressors and oncogenes
|
WO2023230578A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating circulating factors
|
WO2023230566A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating cytokines
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
CN115386597A
(en)
*
|
2022-09-19 |
2022-11-25 |
国家纳米科学中心 |
Transfection auxiliary reagent for improving transfection efficiency and/or transfection precision of gene vector and application thereof
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|